Year Ended December 31, 2021 2020 (2) Cash flows from operating activities Net loss $ (58,543) $ (56,446) Adjustments to reconcile net loss to net cash used in operating activities: Gain on sale of businesses — (32,211) Depreciation and amortization 15,723 16,770 Amortization of debt discounts and deferred financing offering cost 623 6,477 Change in fair value of derivatives liability (4) 4 Impairment of intangible assets, including internal-use software — 729 Change in fair value of Bookings Commitment 2,323 11,168 Stock-based compensation 3,887 2,648 Deferred income taxes, net (78) (23) Provision for bad debt expense 123 133 Loss on Exchange and Prepayment of 2016 Notes 742 — Loss from related party equity method investment — 31,702 Changes in operating assets and liabilities Accounts receivable, net (2,660) 4,786 Inventories — (18) Related party receivables, net 336 77 Prepaid expenses and other current assets (104) 15,143 Accounts payable (1,914) 1,431 Accrued and other current liabilities 1,324 (19,014) Deferred revenue 2,905 (7,376) Related party payables, net 8,066 6,973 Change in operating lease right-of-use assets and liabilities (422) (298) Other assets and liabilities (16) 491 Net cash used in operating activities (27,689) (16,854) Cash flows from investing activities Net proceeds from sale of business — 46,401 Assignment of OpenNMS, net of cash acquired (see Note 19) — (5,475) Purchases of property and equipment, including internal-use software (5,081) (5,672) Purchase of noncontrolling interest (556) — Net cash provided by (used in) investing activities (5,637) 35,254 Cash flows from financing activities Proceeds from insurance promissory note 2,324 1,855 Repayments of insurance promissory note and notes payable (1,810) (1,842) Proceeds from exercises of stock options 291 171 Payment of deferred financing costs, related party (277) — Payment of deferred financing costs (451) — Proceeds from related party convertible notes 62,500 — Proceeds from convertible notes 75,000 — Payment of convertible notes (97,000) — Tax payments related to stock issued, net of stock withheld, for vested equity awards — (739) Net cash provided by (used) in financing activities 40,577 (555) Effect of exchange rate changes on cash, cash equivalents and restricted cash (11) (62) Net increase in cash, cash equivalents and restricted cash 7,240 17,783 Cash, cash equivalents and restricted cash, beginning of period(1) 24,162 6,379 Cash, cash equivalents and restricted cash, end of period(1) $ 31,402 $ 24,162 NantHealth, Inc. Consolidated Statements of Cash Flows (Dollars in thousands) - 100 -
RkJQdWJsaXNoZXIy NTIzOTM0